Study Description
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC). The study consists of Screening, Treatment, and Follow-up periods.
* Treatment Period: all participants who complete screening will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily ET for 36 months (approximately 39 cycles) from the date of first dose. The Treatment Period starts when the patient receives their first dose of ribociclib and ends at the time of the 30-day Safety Follow-up. All treated participants should have a Safety Follow-up call conducted 30 days after the last dose of study treatment.
* Follow-up period: participants will be followed from 30 days after study treatment (i.e., ribociclib) completion/discontinuation (i.e. 30-day Safety Follow-up) until death, withdrawal of consent, lost to follow-up, or until 48 months after the last participant has received their first dose of study treatment (i.e. End of Study \[EOS\]), whichever occurs first.
Interventions
Ansastrozole
Exemestane
Goserelin
Letrozole
Leuprolide
Ribociclib
Eligibility Criteria
Key Inclusion criteria:
* Participant is an adult, male or female ≥ 18 years of age at the time of informed consent form signature (IC).
* Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC) based on the most recently analyzed tissue sample tested by a local laboratory prior to enrollment.
* Participant has HER2- BC defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing based on the most recently analyzed tissue sample.
* Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy.
* For participants with prior ET treatment \> 12 months, restaging is highly recommended (unless contradictory to local regulations) to rule out disease recurrence prior to enrollment.
* The number of participants with prior ET between 12 and 36 months will be capped at 30%. The cap will not apply to Black or African American participants.
* Participant has no contraindication to receive adjuvant ET in the study.
* Participant after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories:
* Anatomic Stage Group III, or
* Anatomic Stage Group IIB, or
* A subset of Anatomic Stage Group IIA.
* Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
* Participant has adequate bone marrow and organ function.
* ECG values assessed by KardiaMobile-6L device, or standard 12-lead ECG per local investigator where KardiaMobile-6L cannot be used, as:
* QTcF interval at Screening \< 450 msec (QT interval using Fridericia's correction).
* Mean resting heart rate 50-99 beats per minute (determined from the ECG).
Key Exclusion criteria:
* Participant with distant metastases of BC beyond regional lymph nodes (Stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.
* Participant is concurrently using other antineoplastic therapy with the exception of adjuvant ET.
* Participant has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate participant participation in the clinical study or compromise compliance with the protocol, or limit life expectancy to ≤5 years.
* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.
* Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.
* Women of child-bearing potential (CBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 21 days after stopping the treatment.
Other inclusion/exclusion criteria may apply
Novartis Investigative Site
Recruiting
Gateshead,New South Wales,2290,Australia
Novartis Investigative Site
Recruiting
East Melbourne,Victoria,3002,Australia
Novartis Investigative Site
Recruiting
Tiwi,Northern Territory,810,Australia
Novartis Investigative Site
Recruiting
Clayton,Victoria,3168,Australia
Novartis Investigative Site
Recruiting
Halifax,Nova Scotia,B3h 2y9,Canada
Novartis Investigative Site
Recruiting
Québec,Quebec,G1s 4l8,Canada
Novartis Investigative Site
Recruiting
Montreal,Quebec,H3t 1e2,Canada
Novartis Investigative Site
Recruiting
Montreal,Quebec,H4a 3j1,Canada
Novartis Investigative Site
Recruiting
Ottawa,Ontario,K1h 8l6,Canada
Novartis Investigative Site
Recruiting
Changchun,Jilin,130021,China
Novartis Investigative Site
Recruiting
Chengdu,Sichuan,610041,China
Novartis Investigative Site
Recruiting
Chengdu,Sichuan,610072,China
Novartis Investigative Site
Recruiting
Hangzhou,Zhejiang,310006,China
Novartis Investigative Site
Recruiting
Shanghai,200032,China
Novartis Investigative Site
Recruiting
Erlangen,91054,Germany
Novartis Investigative Site
Recruiting
Velbert,North Rhine-Westphalia,42551,Germany
Novartis Investigative Site
Recruiting
Mönchengladbach,North Rhine-Westphalia,41061,Germany
Novartis Investigative Site
Recruiting
Weiden,92637,Germany
Novartis Investigative Site
Recruiting
Kiel,24105,Germany
Novartis Investigative Site
Recruiting
München,80637,Germany
Novartis Investigative Site
Recruiting
Munich,Bavaria,81377,Germany
Novartis Investigative Site
Recruiting
Freiburg im Breisgau,Baden-Wurttemberg,79106,Germany
Novartis Investigative Site
Recruiting
Langen,Hesse,63225,Germany
Novartis Investigative Site
Recruiting
Hildesheim,Lower Saxony,31134,Germany
Novartis Investigative Site
Recruiting
Bergisch Gladbach,North Rhine-Westphalia,51465,Germany
Novartis Investigative Site
Recruiting
Dresden,Saxony,01307,Germany
Novartis Investigative Site
Recruiting
Lübeck,Schleswig-Holstein,23563,Germany
Novartis Investigative Site
Recruiting
Augsburg,86179,Germany
Novartis Investigative Site
Recruiting
Berlin,10967,Germany
Novartis Investigative Site
Recruiting
Bottrop,46236,Germany
Novartis Investigative Site
Recruiting
Böblingen,71032,Germany
Novartis Investigative Site
Recruiting
Dessau,06847,Germany
Novartis Investigative Site
Recruiting
Essen,45147,Germany
Novartis Investigative Site
Recruiting
Hamburg,20246,Germany
Novartis Investigative Site
Recruiting
Leipzig,04277,Germany
Novartis Investigative Site
Recruiting
Mainz,55131,Germany
Novartis Investigative Site
Recruiting
Ravensburg,88214,Germany
Novartis Investigative Site
Recruiting
Hong Kong,999077,Hong Kong
Novartis Investigative Site
Recruiting
Kowloon,999999,Hong Kong
Novartis Investigative Site
Recruiting
Tel Aviv,6423906,Israel
Novartis Investigative Site
Recruiting
Beersheba,8457108,Israel
Novartis Investigative Site
Recruiting
Petah Tikva,4941492,Israel
Novartis Investigative Site
Recruiting
Ramat Gan,5265601,Israel
Novartis Investigative Site
Recruiting
Incheon,405 760,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,06351,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,05505,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,Seocho Gu,06591,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,06273,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,02841,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,158-710,Korea, Republic of
Novartis Investigative Site
Recruiting
Bundang Gu,Gyeonggi Do,13620,Korea, Republic of
Novartis Investigative Site
Recruiting
Gyeonggi do,Korea,10408,Korea, Republic of
Novartis Investigative Site
Recruiting
Seongnam Si Gyeonggi Do,463-712,Korea, Republic of
Novartis Investigative Site
Recruiting
Bundang Gu,Gyeonggi-do,13620,South Korea
Novartis Investigative Site
Recruiting
Gyeonggi-do,Korea,10408,South Korea
Novartis Investigative Site
Recruiting
Seoul,Seocho Gu,06591,South Korea
Novartis Investigative Site
Recruiting
Incheon,405 760,South Korea
Novartis Investigative Site
Recruiting
Seongnam Si Gyeonggi Do,463-712,South Korea
Novartis Investigative Site
Recruiting
Seoul,02841,South Korea
Novartis Investigative Site
Recruiting
Seoul,03080,South Korea
Novartis Investigative Site
Recruiting
Seoul,03722,South Korea
Novartis Investigative Site
Recruiting
Seoul,05505,South Korea
Novartis Investigative Site
Recruiting
Seoul,06273,South Korea
Novartis Investigative Site
Recruiting
Seoul,06351,South Korea
Novartis Investigative Site
Recruiting
Seoul,158-710,South Korea
Novartis Investigative Site
Recruiting
Taipei,10002,Taiwan
Novartis Investigative Site
Recruiting
Kaohsiung City,80756,Taiwan
Novartis Investigative Site
Recruiting
Tainan City,71004,Taiwan
Novartis Investigative Site
Recruiting
Taipei,114,Taiwan
Novartis Investigative Site
Recruiting
Hualien City,970,Taiwan
Novartis Investigative Site
Recruiting
Ankara,06230,Turkey
Novartis Investigative Site
Recruiting
Ankara,06520,Turkey
Novartis Investigative Site
Recruiting
Antalya,07070,Turkey
Novartis Investigative Site
Recruiting
Istanbul,34662,Turkey
Novartis Investigative Site
Recruiting
Cankaya Ankara,06560,Turkey
Novartis Investigative Site
Recruiting
Diyarbakir,21000,Turkey
Novartis Investigative Site
Recruiting
Denizli,20070,Turkey
Novartis Investigative Site
Recruiting
Izmir,35575,Turkey
Novartis Investigative Site
Recruiting
Istanbul,34457,Turkey
Novartis Investigative Site
Recruiting
Istanbul,TUR,34098,Turkey
Novartis Investigative Site
Recruiting
Ankara,06500,Turkey
Novartis Investigative Site
Recruiting
Istanbul,34722,Turkey
Novartis Investigative Site
Recruiting
Kecioren Ankara,06010,Turkey
Novartis Investigative Site
Recruiting
Sakarya,54290,Turkey
Novartis Investigative Site
Recruiting
Istanbul,Fatih,34098,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Ankara,Sihhiye-Altindag,06230,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Ankara,Yenimahalle,06500,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Ankara,06520,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Antalya,Konyaalti,07070,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Cankaya Ankara,06560,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Denizli,Kinikli,20070,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Diyarbakır,21000,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Istanbul,Sariyer,34457,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Istanbul,Uskudar,34662,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Istanbul,Kadikoy,34722,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Izmir,Karsiyaka,35575,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Kecioren Ankara,06010,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Sakarya,Adapazari,54290,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Ankara,Bilkent-Cankaya,6800,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Diyarbakır,Sur,21280,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Ankara,Yenimahalle,06200,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Konya,42080,Turkey (Türkiye)
Novartis Investigative Site
Recruiting
Samsun,55200,Turkey (Türkiye)
Alaska Oncology and Hematology LLC
Recruiting
Anchorage,Alaska,99508,United States
Steven Liu
Summit Cancer Care PC
Recruiting
Savannah,Georgia,31405,United States
Karen Moses
Mark A Taylor
Patricia Emfinger
Hope And Healing Care
Recruiting
Hinsdale,Illinois,60521,United States
Hatim Idrees Lokhandwala
Praneetha Achanta
Srilata Gundala
Mercy Medical Center
Recruiting
Baltimore,Maryland,21202,United States
David Andrew Riseberg
Jackson Oncology Associates
Recruiting
Jackson,Mississippi,39202,United States
Justin T Baker
Cancer Center of Kansas
Recruiting
Wichita,Kansas,67214-3728,United States
Shaker R Dakhil
Washington Hospital Center
Recruiting
Washington D.C.,District of Columbia,20010,United States
Ami Chitalia
Ami Chitalia
Clinical Research Alliance
Recruiting
Lake Success,New York,11042,United States
James D Olimpio
Ocala Research Institute, Inc
Recruiting
Ocala,Florida,34474,United States
Anju Vasudevan
Nebraska Cancer Specialists
Recruiting
Omaha,Nebraska,68154,United States
Margaret Barbara Block
Willis-Knighton Cancer Center
Recruiting
Shreveport,Louisiana,71103,United States
Heather Negard
Michelle Mc Cracken
Prakash Peddi
Oregon Oncology Specialists Salem
Recruiting
Salem,Oregon,97301,United States
Heather Alonzo
Janelle Meyer
Northwest Medical Specialties
Recruiting
Tacoma,Washington,98405,United States
Sibel Blau
WA Uni School Of Med
Recruiting
St Louis,Missouri,63110,United States
Katherine Clifton
Katherine Clifton
The Valley Hospital
Recruiting
Ridgewood,New Jersey,07450,United States
Amanda Podolski
Arthur Pacheco
Yodary Reyes
Sarah Cannon Research Institute
Recruiting
Nashville,Tennessee,37203,United States
Denise A Yardley
Rocky Mountain Cancer Centers
Recruiting
Denver,Colorado,80218,United States
Mabel Mardones
Affiliated Oncologists IL
Recruiting
Chicago,Illinois,60415,United States
Angela Malone
Rami Haddad
Investigative Clinical R of Indiana
Recruiting
Indianapolis,Indiana,46260,United States
Leslie Weitman
Ruemu Birhiray
Maryland Oncology Hematology P A
Recruiting
Silver Spring,Maryland,20904,United States
Ana Quinones
Carol Tweed
Minnesota Oncology Hematology P A
Recruiting
Minneapolis,Minnesota,55404,United States
Josphat Lagat
Yang Liu
Renown Regional Medical Center
Recruiting
Reno,Nevada,89502,United States
Heather Braginton
Lee Schwartzberg
Oncology Associates of Oregon PC
Recruiting
Eugene,Oregon,97401-8122,United States
Miho Dougherty
Myrriah Jones
Northwest Cancer Specialists
Recruiting
Portland,Oregon,97210,United States
Jay Andersen
Consultants In Med Onco And Hema
Recruiting
Drexel Hill,Pennsylvania,19026,United States
Alexander Deak
El Paso Texas Oncology
Recruiting
El Paso,Texas,79902,United States
Cristy J McCullough
Ines Sanchez-Rivera
Texas Oncology PA Tyler
Recruiting
Tyler,Texas,75702,United States
Jonathan Caldwell
Sasha Davis
Virginia Oncology Associates
Recruiting
Norfolk,Virginia,23502,United States
Amber Ingram
Michael A. Danso
Providence Regional Cancer System
Recruiting
Lacey,Washington,98503,United States
Mijung Lee
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.